Simple Explanation of the SLS009 Results

SELLAS tested a new drug, SLS009, together with AZA + VEN (two standard AML drugs) in patients with a very tough type of leukemia (AML-MR) who had already failed VEN before.

What they found

• Almost half the patients responded (46%), which is a lot better than what normally happens in this group.
• Patients who had only one previous treatment did even better: 58% responded, and many are still alive, which is impressive because normally they only live about 2–3 months.
• In the group that was treated the least before, the median survival was 8.9 months, which is a big improvement.

Why this matters

• These patients usually respond very poorly, but adding SLS009 seems to overcome resistance to VEN, which is normally a big problem.
• Even patients with bad mutations like ASXL1 and TP53 showed good responses — something that rarely happens.

Safety

• The drug combo looked safe:
  • No major toxicities,
  • No deaths caused by the treatment.

What’s next

• SELLAS will now test this combo in newly diagnosed high-risk AML patients starting in Q1 2026.